Il10 - interleukin 10 Gene
Also Known as CSIF; If2a; Il-10
Species: Mus musculus
About Il10
This gene has 1 transcript (splice variant), 193 orthologues, 3 paralogues and is associated with 137 phenotypes. Low expression observed in reference dataset.
Summary
This gene encodes an anti-inflammatory cytokine that is a member of the class-2 cytokine family. The encoded protein is secreted by cells of both the innate and adaptive immune systems and is crucial for limiting the immune response to a broad range of pathogens. It also has been shown to suppress autoimmune responses. This protein mediates it's immunosuppressive signal through a specific interleukin 10 receptor complex. Aberrant functioning of this gene is associated with numerous immune disorders including graft-versus-host disease, and increased susceptibility to HIV-1 Infection and rheumatoid arthritis. [provided by RefSeq, Sep 2015]
Il10 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_010548.2 | NP_034678.1 | interleukin-10 precursor |
Il10 Protein Structure
IL10: pfam00726 (14 - 173)
- 0
- 100
- 178 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
interleukin-10 |
|
Recombinant Il10 Proteins
| Cat. No. | Product Name | Accession | Purity |
|---|---|---|---|
| HY-P7074A | IL-10 Protein, Mouse (CHO) | P18893 (S19-S178) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P70517 | IL-10 Protein, Mouse | P18893 (S19-S178) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P700188AF | Animal-Free IL-10 Protein, Mouse (His) | P18893 (S19-S178) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-B1829A | Dexamethasone phosphate disodium | 99.94% | Yes | |
| HY-B0809 | Theophylline | 99.97% | Yes | |
| HY-B1051 | Flumethasone | 99.84% | Unkown | |
| HY-B0809R | Theophylline (Standard) | 99.99% | Unkown | |
| HY-B0809A | Theophylline monohydrate | 99.93% | Yes | |
| HY-B1829AR | Dexamethasone phosphate disodium (Standard) | 99.88% | Unkown | |
| HY-B0327 | Irsogladine | 99.88% | Unkown | |
| HY-107909 | Theophylline (sodium glycinate) | / | Unkown | |
| HY-B0809B | Theophylline sodium acetate | / | Unkown |
Clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-B1829 | Dexamethasone phosphate | 98.89% | Phase 4 | |
| HY-13743 | Roquinimex | Inhibitor | 99.69% | Phase 3 |
| HY-160040 | Cobitolimod | Agonist | 97.14% | Phase 3 |
| HY-160040A | Cobitolimod sodium | Agonist | / | Phase 3 |
| HY-13743R | Roquinimex (Standard) | Inhibitor | / | Phase 3 |
| HY-110133 | JTE-607 | Inhibitor | 99.27% | Phase 2 |
| HY-135317 | Emavusertib | 99.97% | Phase 2 | |
| HY-101019 | Ossirene | Inhibitor | 98.0% | Phase 2 |
| HY-111167 | AN-2898 | Inhibitor | / | Phase 2 |
| HY-123625 | R-348 choline | Inhibitor | / | Phase 2 |
| HY-19307 | SB-273005 | 99.94% | Phase 1 | |
| HY-107390 | AX-024 | Inhibitor | 99.73% | Phase 1 |
| HY-107390A | AX-024 hydrochloride | Inhibitor | 99.23% | Phase 1 |
| HY-101757 | NO-prednisolone | Agonist | ≥99.0% | Phase 1 |
| HY-15507 | VGX-1027 | Inhibitor | 99.67% | Phase 1 |
| HY-159657 | PF-07899895 | 98.83% | Phase 1 | |
| HY-111164 | CBS-3595 | Inhibitor | / | Phase 1 |
| HY-P3483 | Maxadilan | / | Phase 1 |
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P990561 | BT-063 | Inhibitor | 99.51% | Phase 2 |
| HY-P991659 | SCH708980 | Inhibitor | / | Phase 2 |
| HY-P99390 | Tepoditamab | Inducer | ≥99% | Phase 1 |
| HY-P991257 | MK-1966 | Inhibitor | 96.17% | Phase 1 |
Pre-clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-18234A | Leupeptin hemisulfate | 99.39% | Yes | |
| HY-141537 | ABR-238901 | Inhibitor | 98.92% | Unkown |
| HY-N0405 | Orientin | Inhibitor | 99.89% | Unkown |
| HY-A0103 | Xanthan gum | 98.0% | Unkown | |
| HY-110353 | CU-T12-9 | Agonist | 99.96% | Unkown |
| HY-23119 | Sodium thiocyanate, GR, 99% | Inhibitor | 99.2% | Unkown |
| HY-130321 | Lauroyl-L-carnitine chloride | Activator | 99.92% | Unkown |
| HY-N6607 | Tryptanthrin | 99.89% | Unkown | |
| HY-N0493 | Pectolinarigenin | 99.98% | Unkown | |
| HY-W013579 | (S)-(+)-Carvone | 99.26% | Unkown | |
| HY-113494 | Sitostanol | Activator | 99.0% | Unkown |
| HY-N0818 | Chikusetsusaponin Iva | Inhibitor | 99.61% | Unkown |
| HY-122586 | BRD6989 | 99.54% | Unkown | |
| HY-109540 | Perfluorohexane | Activator | 98.62% | Unkown |
| HY-78036 | Mesaconic acid | Inhibitor | 99.95% | Unkown |
| HY-N0695 | Schisantherin B | 99.75% | Unkown | |
| HY-N4087 | Platycodin D2 | Inducer | 99.84% | Unkown |
| HY-N15135 | Arabinoxylan (Medium viscosity) | 95.0% | Unkown | |
| HY-124344 | Avenanthramide C | Activator | 99.13% | Unkown |
| HY-147105 | LRH-1 agonist-2 | 98.58% | Unkown | |
| HY-W668775 | Quin-C7 | Antagonist | 99.76% | Unkown |
| HY-N0600 | Ginsenoside F3 | 99.84% | Unkown | |
| HY-P1194 | Spantide I | Antagonist | 99.64% | Unkown |
| HY-161440 | SIK-IN-1 | Inhibitor | 98.91% | Unkown |
| HY-173679 | RBN012811 | 98.79% | Unkown | |
| HY-175479 | GLPG4970 | 99.60% | Unkown | |
| HY-N1940 | β-Anhydroicaritin | Inhibitor | 99.69% | Unkown |
| HY-D1056C1 | Lipopolysaccharides, from S. enterica serotype enteritidis | Activator | / | Unkown |
| HY-130321S | Lauroyl-L-carnitine-d3 chloride | Activator | 99.95% | Unkown |
| HY-130321S1 | Lauroyl-L-carnitine-d9 chloride | Activator | 98.0% | Unkown |
| HY-165613 | Pam2Cys | 99.82% | Unkown | |
| HY-172590 | LZ-07 | 98.27% | Unkown | |
| HY-18234C | Leupeptin Ac-LL hydrochloride | 95.0% | Unkown | |
| HY-14837 | Amizon | Inhibitor | 99.92% | Unkown |
| HY-N14039 | Pinus pinaster bark extract | Activator | 95.79% | Unkown |
| HY-N2492 | (E)-Methyl 4-coumarate | 99.87% | Unkown | |
| HY-155520 | Antileishmanial agent-19 | Inhibitor | 99.45% | Unkown |
| HY-147105A | (+)-LRH-1 agonist-2 | Modulator | 99.38% | Unkown |
| HY-150232 | MALT1-IN-11 | Inhibitor | / | Unkown |
| HY-N4267 | Yangambin | 98.27% | Unkown | |
| HY-N8249 | Cynandione A | Activator | 99.6% | Unkown |
| HY-NP134 | Flagellin from S. typhimurium | 95% | Unkown | |
| HY-P1194A | Spantide I TFA | Antagonist | 99.32% | Unkown |
| HY-W145695 | Chitoheptaose | ≥98.0% | Unkown | |
| HY-117123 | Convulxin | 90% | Unkown | |
| HY-171591 | SIK2-IN-4 | Inhibitor | 99.06% | Unkown |
| HY-N8840 | Laricitrin | 99.36% | Unkown | |
| HY-W041608 | Methylchloroisothiazolinone | / | Unkown | |
| HY-135317B | Emavusertib hydrochloride | / | Unkown | |
| HY-18234 | Leupeptin | / | Unkown | |
| HY-78036R | Mesaconic acid (Standard) | Inhibitor | / | Unkown |
| HY-110067 | VO-OHPic | / | Unkown | |
| HY-113494R | Sitostanol (Standard) | Activator | / | Unkown |
| HY-117461 | Y 25510 | Activator | / | Unkown |
| HY-124665 | LMP-420 | / | Unkown | |
| HY-130054 | Theophylline L-lysine | / | Unkown | |
| HY-143422 | MALT1-IN-3 | Inhibitor | / | Unkown |
| HY-143422A | (R)-MALT1-IN-3 | Inhibitor | / | Unkown |
| HY-143683S | Theophylline-13C2,d6 | / | Unkown | |
| HY-147527 | CDK8-IN-5 | Inhibitor | / | Unkown |
| HY-149365 | SIKs-IN-1 | Inhibitor | / | Unkown |
| HY-160844 | CT-133 | / | Unkown | |
| HY-161441 | SIK-IN-2 | Inhibitor | / | Unkown |
| HY-161442 | SIK-IN-3 | Inhibitor | / | Unkown |
| HY-162600 | CDK8-IN-15 | Inhibitor | / | Unkown |
| HY-167153 | PNA5 | / | Unkown | |
| HY-168091 | YM-I-26 | Inhibitor | / | Unkown |
| HY-168846 | CDK8/19-IN-3 | Inhibitor | / | Unkown |
| HY-172632 | Resolvin D3 methyl ester | Inducer | / | Unkown |
| HY-174395 | CD-10 | / | Unkown | |
| HY-175073 | Ganglioside GT1b (bovine) trisodium | / | Unkown | |
| HY-178144 | FPR2 agonist 5 | / | Unkown | |
| HY-178240 | rel-(1S,2R)-Dihydro bupropion | Inhibitor | / | Unkown |
| HY-178913 | Tyk2-IN-23 | Inhibitor | / | Unkown |
| HY-178945 | KOR agonist 7 | / | Unkown | |
| HY-181822 | BMS-986331 | 99.81% | Unkown | |
| HY-18234B | Leupeptin Ac-LL | / | Unkown | |
| HY-182469 | FuBIG | / | Unkown | |
| HY-183074 | RO8323 | / | Unkown | |
| HY-184654 | MR-39 | / | Unkown | |
| HY-185709 | 2-ARA-LysoPtdEtn | / | Unkown | |
| HY-B0809S1 | Theophylline-d3 | / | Unkown | |
| HY-N17685 | Pseudoginsenoside RT4 | 97.05% | Unkown | |
| HY-N18367 | Lemairamin | / | Unkown | |
| HY-N19801 | N-Palmitoyl-D-glucosamine | / | Unkown | |
| HY-N9980 | Antcin K | Inhibitor | / | Unkown |
| HY-P11004 | A3-APO | Inhibitor | / | Unkown |
| HY-P3483A | Maxadilan TFA | / | Unkown | |
| HY-RS06670 | IL10 Human Pre-designed siRNA Set A | / | Unkown | |
| HY-RS06671 | Il10 Mouse Pre-designed siRNA Set A | / | Unkown | |
| HY-RS06672 | Il10 Rat Pre-designed siRNA Set A | / | Unkown | |
| HY-RS06673 | IL10RA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06674 | IL10RB Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W338346 | Salicylate choline | Inhibitor | / | Unkown |
| HY-110133A | JTE-607 free base | Inhibitor | / | Unkown |
| HY-135317C | Emavusertib tosylate | / | Unkown | |
| HY-135317D | Emavusertib mesylate | / | Unkown | |
| HY-135317E | Emavusertib maleate | / | Unkown | |
| HY-135317F | Emavusertib phosphate | / | Unkown | |
| HY-168384 | M04 | / | Unkown | |
| HY-174614 | Human IL26 mRNA | / | Unkown | |
| HY-174615 | Human IL24 mRNA | / | Unkown | |
| HY-174620 | Human IL22 mRNA | / | Unkown | |
| HY-174629 | Human IL19 mRNA | / | Unkown | |
| HY-174645 | Human IL10RA mRNA | / | Unkown | |
| HY-174646 | Human IL10 mRNA | 90% | Unkown | |
| HY-174657 | Human IFNLR1 mRNA | / | Unkown | |
| HY-174658 | Human IFNL3 mRNA | / | Unkown | |
| HY-174659 | Human IFNL2 mRNA | / | Unkown | |
| HY-174660 | Human IFNL1 mRNA | / | Unkown | |
| HY-177608 | Rat IL10 mRNA | / | Unkown | |
| HY-183478 | Leupeptin hydrochloride | / | Unkown | |
| HY-184814 | C14-Ala-D-Glu-(γ-meso)-LAN-Gly(OH) | / | Unkown | |
| HY-B1829R | Dexamethasone phosphate (Standard) | / | Unkown | |
| HY-N0493R | Pectolinarigenin (Standard) | / | Unkown | |
| HY-N0976 | 1,11b-Dihydro-11b-hydroxymedicarpin | Activator | / | Unkown |
| HY-N15347 | Talaromyketide B | Inhibitor | / | Unkown |
| HY-N20713 | Licocoumarone | / | Unkown | |
| HY-N7697C | Chitohexaose hexahydrochloride | 95.0% | Unkown | |
| HY-RS17431 | Il10ra Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23886 | Il10ra Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W553071 | Cytoxazone | Inhibitor | / | Unkown |
| HY-W745349 | rel-(1S,2R)-Dihydro bupropion-d9 hydrochloride | Inhibitor | / | Unkown |
| HY-W777138 | rel-(1S,2R)-Dihydro bupropion-d9 | Inhibitor | / | Unkown |
| HY-W929472 | 13(S)-HOTrE | 99.9% | Unkown |
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990228 | Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) | Inhibitor | 99.08% | Unkown |
| HY-P990001 | Anti-Mouse IL-10 Antibody (JES5-2A5) | Inhibitor | 98.666% | Unkown |
| HY-P991400 | GSK1995057 | 99.09% | Unkown | |
| HY-P990776 | Vimekofusp | / | Unkown | |
| HY-P991760 | Anti-IL-10 Antibody (JES3-19F1) | Inhibitor | / | Unkown |
| HY-P992037 | Anti-IL-10Rα Antibody | Inhibitor | / | Unkown |
| HY-P992038 | Anti-IL-10RB Antibody | Inhibitor | / | Unkown |
| HY-P992153 | Serrumab | Inhibitor | / | Unkown |
| HY-P992370 | HPN601 | Inhibitor | / | Unkown |